Orphan Status achieved for MPS-I....
Yes, that was the title of a previous post. But I just came across this from the FDA searching for the development of new and better treatments for rare diseases. All good news for PAR and MPS-1 usage, and future testing!
https://mail.yahoo.com/d/folders/1
FDA In Brief: FDA Requests Input on Rare Disease Clinical Trial Networks
The following quote is attributed to Anand Shah, M.D., FDA Deputy Commissioner for Medical and Scientific Affairs:
“The FDA is unleashing innovation for the development of new and better treatments for rare diseases.“For the approximately 7,000 known rare diseases, less than 10% have an FDA-approved treatment available. As drug development for rare diseases can be challenging due to the small number of patients and limited understanding of the variability and progression of the diseases, the FDA is committed to developing bold new approaches to harness the infrastructure of global clinical trial networks.“Today’s announcement is part of our continued work on the Rare Disease Cures Accelerator, which combines scientific expertise with patient perspectives to advance innovation and quality in the drug development pipeline.”Additional Information:
- Today the U.S. Food and Drug Administration announced aRequest for Information and Comment on Rare Disease Clinical Trial Networks. In particular, the FDA is requesting public input on practical steps and successful approaches relating to the start-up, implementation and sustainment of global clinical trials networks, including specific considerations for establishing such networks for a range of rare diseases. Comments will be accepted for 60 days following publication of the docket,FDA-2020-N-0837.
- Today’s request for comments is part of the FDA’s continued work toward building the Rare Disease Cures Accelerator, a cooperative scientific initiative for the development of common, standardized platforms that can improve the characterization of rare diseases, incorporate the patient’s perspective in clinical outcome assessment measures and build clinical trial readiness in the pre-market space.
- Forums
- ASX - By Stock
- PAR
- research reports and media
research reports and media, page-730
-
- There are more pages in this discussion • 3,699 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Featured News
Add PAR (ASX) to my watchlist
(20min delay)
|
|||||
Last
21.0¢ |
Change
0.000(0.00%) |
Mkt cap ! $73.55M |
Open | High | Low | Value | Volume |
21.0¢ | 22.0¢ | 20.5¢ | $222.5K | 1.035M |
Buyers (Bids)
No. | Vol. | Price($) |
---|---|---|
5 | 77810 | 21.0¢ |
Sellers (Offers)
Price($) | Vol. | No. |
---|---|---|
22.0¢ | 23000 | 2 |
View Market Depth
No. | Vol. | Price($) |
---|---|---|
4 | 27810 | 0.210 |
3 | 47926 | 0.205 |
9 | 245349 | 0.200 |
8 | 278635 | 0.195 |
15 | 183884 | 0.190 |
Price($) | Vol. | No. |
---|---|---|
0.220 | 13000 | 1 |
0.225 | 72722 | 5 |
0.230 | 31334 | 3 |
0.235 | 45854 | 2 |
0.240 | 65386 | 4 |
Last trade - 16.10pm 11/10/2024 (20 minute delay) ? |
Featured News
PAR (ASX) Chart |